Fluoroquinolones for the treatment of tuberculosis in children

Tuberculosis

Volumn 95, Issue 3, 2015, Pages 229-245

  Thee, S ^a,b   Garcia Prats, A J ^a   Donald, P R ^a   Hesseling, A C ^a   Schaaf, H S ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Children; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Pharmacokinetics; Safety

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD DISEASE; CHONDROPATHY; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TISSUE DISTRIBUTION; VOLUME OF DISTRIBUTION; AGE; MICROBIOLOGY; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; RISK FACTOR; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AGE FACTORS; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; LEVOFLOXACIN; OFLOXACIN; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84929282710     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2015.02.037     Document Type: Review

References (282)

1. A. Adefurin, H. Sammons, E. Jacqz-Aigrain, and I. Choonara Ciprofloxacin safety in paediatrics: a systematic review Arch Dis Child 96 9 2011 874 880
2. F.C. Adler-Shohet, J. Low, M. Carson, H. Girma, and J. Singh Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis Pediatr Infect Dis J 33 6 2014 664 666
3. Z. Ahmad, S. Tyagi, A. Minkowski, C.A. Peloquin, J.H. Grosset, and E.L. Nuermberger Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis Am J Respir Crit Care Med 188 1 2013 97 102
4. S.D. Ahuja, D. Ashkin, M. Avendano, R. Banerjee, M. Bauer, J.N. Bayona, M.C. Becerra, A. Benedetti, M. Burgos, R. Centis, E.D. Chan, C.Y. Chiang, H. Cox, L. D'Ambrosio, K. DeRiemer, N.H. Dung, D. Enarson, D. Falzon, K. Flanagan, J. Flood, M.L. Garcia-Garcia, N. Gandhi, R.M. Granich, M.G. Hollm-Delgado, T.H. Holtz, M.D. Iseman, L.G. Jarlsberg, S. Keshavjee, H.R. Kim, W.J. Koh, J. Lancaster, C. Lange, W.C. de Lange, V. Leimane, C.C. Leung, J. Li, D. Menzies, G.B. Migliori, S.P. Mishustin, C.D. Mitnick, M. Narita, P. O'Riordan, M. Pai, D. Palmero, S.K. Park, G. Pasvol, J. Pena, C. Perez-Guzman, M.I. Quelapio, A. Ponce-de-Leon, V. Riekstina, J. Robert, S. Royce, H.S. Schaaf, K.J. Seung, L. Shah, T.S. Shim, S.S. Shin, Y. Shiraishi, J. Sifuentes-Osornio, G. Sotgiu, M.J. Strand, P. Tabarsi, T.E. Tupasi, R. van Altena, M. Van der Walt, T.S. Van der Werf, M.H. Vargas, P. Viiklepp, J. Westenhouse, W.W. Yew, and J.J. Yim Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients PLoS Med 9 8 2012 e1001300
5. G.J. Alangaden, E.K. Manavathu, S.B. Vakulenko, N.M. Zvonok, and S.A. Lerner Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients Antimicrob Agents Chemother 39 8 1995 1700 1703
6. J.W. Alffenaar, R. van Altena, H.J. Bokkerink, G.J. Luijckx, D. van Soolingen, R.E. Aarnoutse, and T.S. van der Werf Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis Clin Infect Dis Off Publ Infect Dis Soc Am 49 7 2009 1080 1082
7. A.A. Alghasham, and M.C. Nahata Clinical use of fluoroquinolones in children Ann Pharmacother 34 3 2000 347 359 quiz 413-4
8. A.K. Ali Peripheral neuropathy and Guillain-Barre syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis Ann Epidemiol 24 4 2014 279 285
9. E.J. Alvirez-Freites, J.L. Carter, and M.H. Cynamon In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis Antimicrob Agents Chemother 46 4 2002 1022 1025
10. K. Andries, T. Gevers, and N. Lounis Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis Antimicrob Agents Chemother 54 11 2010 4540 4544
11. K.A. Angeby, P. Jureen, C.G. Giske, E. Chryssanthou, E. Sturegard, M. Nordvall, A.G. Johansson, J. Werngren, G. Kahlmeter, S.E. Hoffner, and T. Schon Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data J Antimicrob Chemother 65 5 2010 946 952
12. A. Aubry, X.S. Pan, L.M. Fisher, V. Jarlier, and E. Cambau Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity Antimicrob Agents Chemother 48 4 2004 1281 1288
13. O. Bakiner, M.E. Ertorer, F.E. Haydardedeoglu, E. Bozkirli, N.B. Tutuncu, and N.G. Demirag Subclinical hypothyroidism is characterized by increased QT interval dispersion among women Med Princ Pract Int J Kuwait Univ Health Sci Centre 17 5 2008 390 394
14. P. Ball, L. Mandell, Y. Niki, and G. Tillotson Comparative tolerability of the newer fluoroquinolone antibacterials Drug Saf Int J Med Toxicol Drug Exp 21 5 1999 407 421
15. V.V. Banu Rekha, K. Rajaram, A.S. Kripasankar, R. Parthasarathy, K.C. Umapathy, I. Sheikh, N. Selvakumar, M. Victor, C. Niruparani, R. Sridhar, and M.S. Jawahar Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions Natl Med J India 25 4 2012 196 200
16. M.C. Becerra, S.C. Appleton, M.F. Franke, K. Chalco, F. Arteaga, J. Bayona, M. Murray, S.S. Atwood, and C.D. Mitnick Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study Lancet 377 9760 2011 147 152
17. S. Belard, W. Isaacs, F. Black, L. Bateman, L. Madolo, J. Munro, L. Workman, M.P. Grobusch, and H.J. Zar Treatment of childhood tuberculosis: caregivers' practices and perceptions in Cape Town, South Africa Paediatr Int Child Health 35 1 2015 24 28
18. S.E. Berning The role of fluoroquinolones in tuberculosis today Drugs 61 1 2001 9 18
19. S.E. Berning, L. Madsen, M.D. Iseman, and C.A. Peloquin Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections Am J Respir Crit Care Med 151 6 1995 2006 2009
20. D.B. Bethell, N.P. Day, N.M. Dung, C. McMullin, H.T. Loan, D.T. Tam, L.T. Minh, N.T. Linh, N.Q. Dung, H. Vinh, A.P. MacGowan, L.O. White, and N.J. White Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever Antimicrob Agents Chemother 40 9 1996 2167 2172
21. Y. Bhusal, C.M. Shiohira, and N. Yamane Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis Int J Antimicrob Agents 26 4 2005 292 297
22. S. Bonora, A. Mondo, L. Trentini, A. Calcagno, A. Lucchini, and G. Di Perri Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins J Infect 57 1 2008 78 81
23. W.R. Bowie, V. Willetts, and P.J. Jewesson Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin Antimicrob Agents Chemother 33 10 1989 1778 1782
24. J.S. Bradley, R.E. Kauffman, D.A. Balis, C.M. Duffy, P.G. Gerbino, S.D. Maldonado, and G.J. Noel Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin Pediatrics 134 1 2014 e146 e153
25. A. Briasoulis, V. Agarwal, and W.J. Pierce QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications Cardiology 120 2 2011 103 110
26. F. Brossier, N. Veziris, A. Aubry, V. Jarlier, and W. Sougakoff Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates J Clin Microbiol 48 5 2010 1683 1689
27. J.E. Burkhardt, J.N. Walterspiel, and U.B. Schaad Quinolone arthropathy in animals versus children Clin Infect Dis Off Publ Infect Dis Soc Am 25 5 1997 1196 1204
28. W.J. Burman, S. Goldberg, J.L. Johnson, G. Muzanye, M. Engle, A.W. Mosher, S. Choudhri, C.L. Daley, S.S. Munsiff, Z. Zhao, A. Vernon, and R.E. Chaisson Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis Am J Respir Crit Care Med 174 3 2006 331 338
29. E. Cambau, W. Sougakoff, M. Besson, C. Truffot-Pernot, J. Grosset, and V. Jarlier Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin J Infect Dis 170 2 1994 479 483
30. E.B. Chahine, L.R. Karaoui, and H. Mansour Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis Ann Pharmacother 48 1 2014 107 115
31. M. Chalumeau, S. Tonnelier, P. D'Athis, J.M. Treluyer, D. Gendrel, G. Breart, G. Pons I. Pediatric Fluoroquinolone Safety Study Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France Pediatrics 111 6 Pt 1 2003 e714 e719
32. H.F. Chambers, T. Kocagoz, T. Sipit, J. Turner, and P.C. Hopewell Activity of amoxicillin/clavulanate in patients with tuberculosis Clin Infect Dis Off Publ Infect Dis Soc Am 26 4 1998 874 877
33. K.C. Chang, and C.C. Leung Moxifloxacin versus ethambutol in initial tuberculosis treatment Lancet 373 9682 2009 2197 2198 author reply 2198-9
34. U. Chauhan, P. Shanbag, and P. Kashid Ofloxacin-induced hallucinations Indian J Pharmacol 45 2 2013 189 190
35. J.V. Chauny, M. Lorrot, S. Prot-Labarthe, A. De Lauzanne, C. Doit, T. Gereral, and O. Bourdon Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases Pediatr Infect Dis J 31 12 2012 1309 1311
36. A.F. Cheng, W.W. Yew, E.W. Chan, M.L. Chin, M.M. Hui, and R.C. Chan Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates Antimicrob Agents Chemother 48 2 2004 596 601
37. C.Y. Chiang, D.A. Enarson, M.C. Yu, K.J. Bai, R.M. Huang, C.J. Hsu, J. Suo, and T.P. Lin Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Eur Respir J 28 5 2006 980 985
38. S. Chien, T.G. Wells, J.L. Blumer, G.L. Kearns, J.S. Bradley, J.A. Bocchini Jr., J. Natarajan, S. Maldonado, and G.J. Noel Levofloxacin pharmacokinetics in children J Clin Pharmacol 45 2 2005 153 160
39. S.C. Chien, A.T. Chow, J. Natarajan, R.R. Williams, F.A. Wong, M.C. Rogge, and R.K. Nayak Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects Antimicrob Agents Chemother 41 7 1997 1562 1565
40. S.C. Chien, A.T. Chow, M.C. Rogge, R.R. Williams, and C.W. Hendrix Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine Antimicrob Agents Chemother 41 8 1997 1765 1769
41. S.C. Chien, M.C. Rogge, L.G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R.R. Williams, C.L. Fowler, W.K. Cheung, and A.T. Chow Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses Antimicrob Agents Chemother 41 10 1997 2256 2260
42. S.C. Chien, F.A. Wong, C.L. Fowler, S.V. Callery-D'Amico, R.R. Williams, R. Nayak, and A.T. Chow Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers Antimicrob Agents Chemother 42 4 1998 885 888
43. N. Chierakul, D. Klomsawat, S. Chulavatnatol, and B. Chindavijak Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 5 3 2001 278 282
44. E. Chigutsa, S. Meredith, L. Wiesner, N. Padayatchi, J. Harding, P. Moodley, W.R. Mac Kenzie, M. Weiner, H. McIlleron, and C.M. Kirkpatrick Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis Antimicrob Agents Chemother 56 7 2012 3857 3863
45. W. Christ, and B. Esch Adverse reactions to fluoroquinolones in adults and children Infect Dis Clin Pract 3 Suppl. 3 1994 168 176
46. W. Christ, T. Lehnert, and B. Ulbrich Specific toxicologic aspects of the quinolones Rev Infect Dis 10 Suppl. 1 1988 S141 S146
47. S. Chulavatnatol, B. Chindavijak, N. Chierakul, and D. Klomsawat Pharmacokinetics of ofloxacin in drug-resistant tuberculosis J Med Assoc Thail Chotmaihet thangphaet 86 8 2003 781 788
48. V. Chysky, K. Kapila, R. Hullmann, G. Arcieri, P. Schacht, and R. Echols Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation Infection 19 4 1991 289 296
49. L.R. Codecasa, G. Ferrara, M. Ferrarese, M.A. Morandi, V. Penati, C. Lacchini, P. Vaccarino, and G.B. Migliori Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs Respir Med 100 9 2006 1566 1572
50. M.B. Conde, A. Efron, C. Loredo, G.R. De Souza, N.P. Graca, M.C. Cezar, M. Ram, M.A. Chaudhary, W.R. Bishai, A.L. Kritski, and R.E. Chaisson Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial Lancet 373 9670 2009 1183 1189
51. J.E. Conte Jr., J.A. Golden, M. McIver, and E. Zurlinden Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects Int J Antimicrob Agents 28 2 2006 114 121
52. R. Cremades, J.C. Rodriguez, E. Garcia-Pachon, A. Galiana, M. Ruiz-Garcia, P. Lopez, and G. Royo Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model J Antimicrob Chemother 66 10 2011 2281 2283
53. B.D. Damle, V. Mummaneni, S. Kaul, and C. Knupp Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin Antimicrob Agents Chemother 46 2 2002 385 391
54. G.R. Davies, and E.L. Nuermberger Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs Tuberculosis 88 Suppl. 1 2008 S65 S74
55. M.B. De Valle, V. Av Klinteberg, N. Alem, R. Olsson, and E. Bjornsson Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic Alimentary Pharmacol Ther 24 8 2006 1187 1195
56. J.L. Demolis, D. Kubitza, L. Tenneze, and C. Funck-Brentano Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects Clin Pharmacol Ther 68 6 2000 658 666
57. R.A. Devasia, A. Blackman, T. Gebretsadik, M. Griffin, A. Shintani, C. May, T. Smith, N. Hooper, F. Maruri, J. Warkentin, E. Mitchel, and T.R. Sterling Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure Am J Respir Crit Care Med 180 4 2009 365 370
58. R.A. Devasia, A. Blackman, C. May, S. Eden, T. Smith, N. Hooper, F. Maruri, C. Stratton, A. Shintani, and T.R. Sterling Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance J Antimicrob Chemother 63 6 2009 1173 1178
59. A.H. Diacon, R. Dawson, F. von Groote-Bidlingmaier, G. Symons, A. Venter, P.R. Donald, C. van Niekerk, D. Everitt, H. Winter, P. Becker, C.M. Mendel, and M.K. Spigelman 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Lancet 380 9846 2012 986 993
60. A.H. Diacon, and P.R. Donald The early bactericidal activity of antituberculosis drugs Expert Rev Anti Infect Ther 12 2 2014 223 237
61. A.H. Diacon, P.R. Donald, A. Pym, M. Grobusch, R.F. Patientia, R. Mahanyele, N. Bantubani, R. Narasimooloo, T. De Marez, R. van Heeswijk, N. Lounis, P. Meyvisch, K. Andries, and D.F. McNeeley Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance Antimicrob Agents Chemother 56 6 2012 3271 3276
62. P.R. Donald Cerebrospinal fluid concentrations of antituberculosis agents in adults and children Tuberculosis 90 5 2010 279 292
63. P.R. Donald, and A.H. Diacon The early bactericidal activity of anti-tuberculosis drugs: a literature review Tuberculosis 88 Suppl. 1 2008 S75 S83
64. P.R. Donald, and H.S. Schaaf Old and new drugs for the treatment of tuberculosis in children Paediatr Respir Rev 8 2 2007 134 141
65. S.E. Dorman, J.L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C.M. Heilig, J. Bernardo, S. Choudhri, J.H. Grosset, E. Guy, P. Guyadeen, M.C. Leus, G. Maltas, D. Menzies, E.L. Nuermberger, M. Villarino, A. Vernon, and R.E. Chaisson Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis Am J Respir Crit Care Med 180 3 2009 273 280
66. P.C. Drobac, J.S. Mukherjee, J.K. Joseph, C. Mitnick, J.J. Furin, H. del Castillo, S.S. Shin, and M.C. Becerra Community-based therapy for children with multidrug-resistant tuberculosis Pediatrics 117 6 2006 2022 2029
67. G.L. Drusano, N. Sgambati, A. Eichas, D. Brown, R. Kulawy, and A. Louie Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system mBio 2 4 2011 e00108-11
68. W.M. el-Sadr, D.C. Perlman, J.P. Matts, E.T. Nelson, D.L. Cohn, N. Salomon, M. Olibrice, F. Medard, K.D. Chirgwin, D. Mildvan, B.E. Jones, E.E. Telzak, O. Klein, L. Heifets, and R. Hafner Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG) Clin Infect Dis Off Publ Infect Dis Soc Am 26 5 1998 1148 1158
69. S. Esposito, S. Bosis, L. Canazza, R. Tenconi, M. Torricelli, and N. Principi Peritoneal tuberculosis due to multidrug-resistant Mycobacterium tuberculosis Pediatr Int Off J Jpn Pediatr Soc 55 2 2013 e20 e22
70. D. Ettehad, H.S. Schaaf, J.A. Seddon, G.S. Cooke, and N. Ford Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis Lancet Infect Dis 12 6 2012 449 456
71. D. Falzon, N. Gandhi, G.B. Migliori, G. Sotgiu, H.S. Cox, T.H. Holtz, M.G. Hollm-Delgado, S. Keshavjee, K. DeRiemer, R. Centis, L. D'Ambrosio, C.G. Lange, M. Bauer, and D. Menzies Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Eur Respir J 42 1 2013 156 168
72. L. Fattorini, D. Tan, E. Iona, M. Mattei, F. Giannoni, L. Brunori, S. Recchia, and G. Orefici Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice Antimicrob Agents Chemother 47 1 2003 360 362
73. K. Feja, E. McNelley, C.S. Tran, J. Burzynski, and L. Saiman Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003 Pediatr Infect Dis J 27 10 2008 907 912
74. C.H. Fenlon, and M.H. Cynamon Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare Antimicrob Agents Chemother 29 3 1986 386 388
75. P. Filippini, E. Iona, G. Piccaro, P. Peyron, O. Neyrolles, and L. Fattorini Activity of drug combinations against dormant Mycobacterium tuberculosis Antimicrob Agents Chemother 54 6 2010 2712 2715
76. D.N. Fish, and A.T. Chow The clinical pharmacokinetics of levofloxacin Clin Pharmacokinet 32 2 1997 101 119
77. C. Forster, K. Kociok, M. Shakibaei, H.J. Merker, and R. Stahlmann Quinolone-induced cartilage lesions are not reversible in rats Arch Toxicol 70 8 1996 474 481
78. S. Garazzino, C. Scolfaro, I. Raffaldi, A.M. Barbui, L. Luccoli, and P.A. Tovo Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience Pediatr Pulmonol 2013
79. A. Garcia-Prats The pharmacokinetics and safety of the fluoroquinolones for the treatment and prevention of drug-resistant tuberculosis in HIV-infected and -uninfected children 44th union world conference on lung health, symposium on MDR-TB in children and adolescents 2013
80. A.J. Garcia-Prats, P.R. Donald, A.C. Hesseling, and H.S. Schaaf Second-line antituberculosis drugs in children: a commissioned review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines 2013 [cited 2014 3 August]; Available from: http://www.who.int/selection-medicines/committees/expert/19/applications/TB/en/
81. A. Garcia-Tapia, J.C. Rodriguez, M. Ruiz, and G. Royo Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis Chemotherapy 50 5 2004 211 213
82. R. Garraffo, T. Lavrut, J. Durant, L. Heripret, M.A. Serini, B. Dunais, and P. Dellamonica In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils Clin Drug Invest 25 10 2005 643 650
83. M. Gegia, H.E. Jenkins, I. Kalandadze, and J. Furin Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011 Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 17 5 2013 624 629
84. I. Germanakis, E. Galanakis, F. Parthenakis, P.E. Vardas, and M. Kalmanti Clarithromycin treatment and QT prolongation in childhood Acta Paediatr 95 12 2006 1694 1696
85. S.H. Gillespie, and O. Billington Activity of moxifloxacin against mycobacteria J Antimicrob Chemother 44 3 1999 393 395
86. S.H. Gillespie, A.M. Crook, T.D. McHugh, C.M. Mendel, S.K. Meredith, S.R. Murray, F. Pappas, P.P. Phillips, and A.J. Nunn Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis N. Engl J Med 371 17 2014 1577 1587
87. S.H. Gillespie, R.D. Gosling, L. Uiso, N.E. Sam, E.G. Kanduma, and T.D. McHugh Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis J Antimicrob Chemother 56 6 2005 1169 1171
88. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai Fluoroquinolones, tuberculosis, and resistance Lancet Infect Dis 3 7 2003 432 442
89. A.S. Ginsburg, R. Sun, H. Calamita, C.P. Scott, W.R. Bishai, and J.H. Grosset Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model Antimicrob Agents Chemother 49 9 2005 3977 3979
90. S.D. Goodwin, H.A. Gallis, A.T. Chow, F.A. Wong, S.C. Flor, and J.A. Bartlett Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection Antimicrob Agents Chemother 38 4 1994 799 804
91. E.A. Gorzynski, S.I. Gutman, and W. Allen Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin Antimicrob Agents Chemother 33 4 1989 591 592
92. R.D. Gosling, L.O. Uiso, N.E. Sam, E. Bongard, E.G. Kanduma, M. Nyindo, R.W. Morris, and S.H. Gillespie The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis Am J Respir Crit Care Med 168 11 2003 1342 1345
93. R. Grady Safety profile of quinolone antibiotics in the pediatric population Pediatr Infect Dis J 22 12 2003 1128 1132
94. S.M. Graham, D.J. Bell, S. Nyirongo, R. Hartkoorn, S.A. Ward, and E.M. Molyneux Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection Antimicrob Agents Chemother 50 2 2006 407 413
95. J.F. Graumlich, S. Habis, R.R. Avelino, S.M. Salverson, M. Gaddamanugu, K. Jamma, and J.C. Aldag Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study Pharmacotherapy 25 10 2005 1296 1302
96. V. Guerrini, M. De Rosa, S. Pasquini, C. Mugnaini, A. Brizzi, A.M. Cuppone, G. Pozzi, and F. Corelli New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains Tuberculosis 93 4 2013 405 411
97. I. Guillemin, V. Jarlier, and E. Cambau Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria Antimicrob Agents Chemother 42 8 1998 2084 2088
98. T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, and G.L. Drusano Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling J Infect Dis 190 9 2004 1642 1651
99. P. Gurumurthy, G. Ramachandran, A.K. Hemanth Kumar, S. Rajasekaran, C. Padmapriyadarsini, S. Swaminathan, P. Venkatesan, L. Sekar, S. Kumar, O.R. Krishnarajasekhar, and P. Paramesh Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis Clin Infect Dis Off Publ Infect Dis Soc Am 38 2 2004 280 283
100. B. Hampel, R. Hullmann, and H. Schmidt Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report Pediatr Infect Dis J 16 1 1997 127 129 discussion 160-2
101. G. Hayem, P.X. Petit, M. Levacher, C. Gaudin, M.F. Kahn, and J.J. Pocidalo Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents Antimicrob Agents Chemother 38 2 1994 243 247
102. D. Herbert, C.N. Paramasivan, P. Venkatesan, G. Kubendiran, R. Prabhakar, and D.A. Mitchison Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis Antimicrob Agents Chemother 40 10 1996 2296 2299
103. S. Hess, T. Hospach, R. Nossal, G. Dannecker, K. Magdorf, and F. Uhlemann Life-threatening disseminated tuberculosis as a complication of TNF-alpha blockade in an adolescent Eur J Pediatr 170 10 2011 1337 1342
104. D. Hillemann, S. Rusch-Gerdes, and E. Richter Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens J Clin Microbiol 47 6 2009 1767 1772
105. S.E. Hoffner, L. Gezelius, and B. Olsson-Liljequist In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis J Antimicrob Chemother 40 6 1997 885 888
106. Hong Kong Chest Service/British Medical Research Council A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin Tuber Lung Dis Off J Int Union against Tuberc Lung Dis 73 1 1992 59 67
107. D.C. Hooper Mechanisms of action of antimicrobials: focus on fluoroquinolones Clin Infect Dis Off Publ Infect Dis Soc Am 32 Suppl. 1 2001 S9 S15
108. Y. Hu, A.R. Coates, and D.A. Mitchison Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis Antimicrob Agents Chemother 47 2 2003 653 657
109. C. Immanuel, A.K. Hemanthkumar, P. Gurumurthy, and P. Venkatesan Dose related pharmacokinetics of ofloxacin in healthy volunteers Int J Tuberc Lung Dis Off J Int Union against Tuberc Lung Dis 6 11 2002 1017 1022
110. K.R. Jacobson, D.B. Tierney, C.Y. Jeon, C.D. Mitnick, and M.B. Murray Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis Clin Infect Dis Off Publ Infect Dis Soc Am 51 1 2010 6 14
111. M.S. Jawahar, V.V. Banurekha, C.N. Paramasivan, F. Rahman, R. Ramachandran, P. Venkatesan, R. Balasubramanian, N. Selvakumar, C. Ponnuraja, A.S. Iliayas, N.P. Gangadevi, B. Raman, D. Baskaran, S.R. Kumar, M.M. Kumar, V. Mohan, S. Ganapathy, V. Kumar, G. Shanmugam, N. Charles, M.R. Sakthivel, K. Jagannath, C. Chandrasekar, R.T. Parthasarathy, and P.R. Narayanan Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients PLoS One 8 7 2013 e67030
112. H.E. Jenkins, A.W. Tolman, C.M. Yuen, J.B. Parr, S. Keshavjee, C.M. Perez-Velez, M. Pagano, M.C. Becerra, and T. Cohen Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates Lancet 383 9928 2014 1572 1579
113. B. Ji, N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis Antimicrob Agents Chemother 42 8 1998 2066 2069
114. B. Ji, N. Lounis, C. Truffot-Pernot, and J. Grosset In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis Antimicrob Agents Chemother 39 6 1995 1341 1344
115. B. Ji, C. Truffot-Pernot, and J. Grosset In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis Tubercle 72 3 1991 181 186
116. R.H. Jiang, H.B. Xu, and L. Li Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study Int J Antimicrob Agents 42 1 2013 36 41
117. A. Jindani A multicentre randomized clinical trial to evaluate high-dose rifapentine with a quinolone for treatment of pulmonary TB: the RIFAQUIN trial 20th conference on retroviruses and opportunistic infections 2013 [Atlanta]
118. A. Jindani, V.R. Aber, E.A. Edwards, and D.A. Mitchison The early bactericidal activity of drugs in patients with pulmonary tuberculosis Am Rev Respir Dis 121 6 1980 939 949
119. J.L. Johnson, D.J. Hadad, W.H. Boom, C.L. Daley, C.A. Peloquin, K.D. Eisenach, D.D. Jankus, S.M. Debanne, E.D. Charlebois, E. Maciel, M. Palaci, and R. Dietze Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 10 6 2006 605 612
120. J.C. Johnston, N.C. Shahidi, M. Sadatsafavi, and J.M. Fitzgerald Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis PLoS One 4 9 2009 e6914
121. K.M. Kam, C.W. Yip, T.L. Cheung, H.S. Tang, O.C. Leung, and M.Y. Chan Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility Microb Drug Resist 12 1 2006 7 11
122. J. Kang, L. Wang, X.L. Chen, D.J. Triggle, and D. Rampe Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG Mol Pharmacol 59 1 2001 122 126
123. S.P. Klemens, C.A. Sharpe, M.C. Rogge, and M.H. Cynamon Activity of levofloxacin in a murine model of tuberculosis Antimicrob Agents Chemother 38 7 1994 1476 1479
124. C.A. Knupp, and R.H. Barbhaiya A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic Biopharm Drug Dispos 18 1 1997 65 77
125. T. Kocagoz, C.J. Hackbarth, I. Unsal, E.Y. Rosenberg, H. Nikaido, and H.F. Chambers Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra Antimicrob Agents Chemother 40 8 1996 1768 1774
126. W.J. Koh, S.H. Lee, Y.A. Kang, C.H. Lee, J.C. Choi, J.H. Lee, S.H. Jang, K.H. Yoo, K.H. Jung, K.U. Kim, S.B. Choi, Y.J. Ryu, K. Chan Kim, S. Um, Y.S. Kwon, Y.H. Kim, W.I. Choi, K. Jeon, Y.I. Hwang, S.J. Kim, Y.S. Lee, E.Y. Heo, J. Lee, Y.W. Ki, T.S. Shim, and J.J. Yim Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis Am J Respir Crit Care Med 188 7 2013 858 864
127. S. Kohno, H. Koga, M. Kaku, S. Maesaki, and K. Hara Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis Chest 102 6 1992 1815 1818
128. I. Kontsevaya, S. Mironova, V. Nikolayevskyy, Y. Balabanova, S. Mitchell, and F. Drobniewski Evaluation of two molecular assays for rapid detection of Mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance settings J Clin Microbiol 49 8 2011 2832 2837
129. A. Kruuner, M.D. Yates, and F.A. Drobniewski Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis J Clin Microbiol 44 3 2006 811 818
130. G. Kubendiran, C.N. Paramasivan, S. Sulochana, and D.A. Mitchison Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis J Chemother 18 6 2006 617 623
131. V. Lalande, C. Truffot-Pernot, A. Paccaly-Moulin, J. Grosset, and B. Ji Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice Antimicrob Agents Chemother 37 3 1993 407 413
132. J.P. Lanoix, F. Betoudji, and E. Nuermberger Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis Antimicrob Agents Chemother 58 4 2014 2316 2321
133. D.V. Lardizabal Intracranial hypertension and levofloxacin: a case report Headache 49 2 2009 300 301
134. A.J. Lenaerts, V. Gruppo, J.V. Brooks, and I.M. Orme Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice Antimicrob Agents Chemother 47 2 2003 783 785
135. F. Li, P. Nandy, S. Chien, G.J. Noel, and C.W. Tornoe Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children Antimicrob Agents Chemother 54 1 2010 375 379
136. H.H. Liu Safety profile of the fluoroquinolones: focus on levofloxacin Drug Saf Int J Med Toxicol Drug Exp 33 5 2010 353 369
137. H. Lode, G. Hoffken, M. Boeckk, N. Deppermann, K. Borner, and P. Koeppe Quinolone pharmacokinetics and metabolism J Antimicrob Chemother 26 Suppl. B 1990 41 49
138. H. Lode, G. Hoffken, P. Olschewski, B. Sievers, A. Kirch, K. Borner, and P. Koeppe Pharmacokinetics of ofloxacin after parenteral and oral administration Antimicrob Agents Chemother 31 9 1987 1338 1342
139. N. Lounis, A. Bentoucha, C. Truffot-Pernot, B. Ji, R.J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice Antimicrob Agents Chemother 45 12 2001 3482 3486
140. N. Lounis, B. Ji, C. Truffot-Pernot, and J. Grosset Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 41 3 1997 607 610
141. G.E. Louw, R.M. Warren, N.C. Gey van Pittius, R. Leon, A. Jimenez, R. Hernandez-Pando, C.R. McEvoy, M. Grobbelaar, M. Murray, P.D. van Helden, and T.C. Victor Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux Am J Respir Crit Care Med 184 2 2011 269 276
142. T. Lu, and K. Drlica In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents J Antimicrob Chemother 52 6 2003 1025 1028
143. C. Magis-Escurra, H.M. Later-Nijland, J.W. Alffenaar, J. Broeders, D.M. Burger, R. van Crevel, M.J. Boeree, A.R. Donders, R. van Altena, T.S. van der Werf, and R.E. Aarnoutse Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin Int J Antimicrob Agents 2014
144. V. Malerczyk, M. Verho, A. Korn, and R. Rangoonwala Relative bioavailability of ofloxacin tablets in comparison to oral solution Curr Med Res Opin 10 8 1987 514 520
145. S. Malik, M. Willby, D. Sikes, O.V. Tsodikov, and J.E. Posey New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations PLoS One 7 6 2012 e39754
146. K. Manika, K. Chatzika, K. Zarogoulidis, and I. Kioumis Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring? Eur Respir J 40 4 2012 1051 1053
147. S. Mase, J. Jereb, C.L. Daley, D. Fred, A. Loeffler, and C. Peloquin Pharmacokinetics of levofloxacin in pediatric MDR TB cases and contacts, federated states of micronesia Am J Respir Crit Care Med American Thoracic Society international conference abstracts 2011 183 2011 A1837. Available at: http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1-MeetingAbstracts.A1837
148. S. Mase, J. Jereb, F. Martin, C. Daley, D. Fred, K. Briand, A. Loeffler, S. Bamrah, R. Brostrom, C. Peloquin, and T. Chorba Pharmacokinetics studies of levofloxacin in children treated for, or exposed to, multidrug-resistant tuberculosis - United States affiliated Pacific Islands, 2010-2011 Am J Respir Crit Care Med American Thoracic Society international conference Abstracts 2012 2012 A6778. Available at: http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1-MeetingAbstracts.A6778
149. M. McGrath, N.C. Gey van Pittius, F.A. Sirgel, P.D. Van Helden, and R.M. Warren Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations Antimicrob Agents Chemother 58 5 2014 2912 2915
150. K. Mdluli, and Z. Ma Mycobacterium tuberculosis DNA gyrase as a target for drug discovery Infect Disord Drug Targets 7 2 2007 159 168
151. A.J. Mehlhorn, and D.A. Brown Safety concerns with fluoroquinolones Ann Pharmacother 41 11 2007 1859 1866
152. C.S. Merle, K. Fielding, O.B. Sow, M. Gninafon, M.B. Lo, T. Mthiyane, J. Odhiambo, E. Amukoye, B. Bah, F. Kassa, A. N'Diaye, R. Rustomjee, B.C. de Jong, J. Horton, C. Perronne, C. Sismanidis, O. Lapujade, P.L. Olliaro, C. Lienhardt, and O.F.G.f.T. Project A four-month gatifloxacin-containing regimen for treating tuberculosis N Engl J Med 371 17 2014 1588 1598
153. E. Miyazaki, M. Miyazaki, J.M. Chen, R.E. Chaisson, and W.R. Bishai Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis Antimicrob Agents Chemother 43 1 1999 85 89
154. K.C. Mohanty, and T.M. Dhamgaye Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis Chest 104 4 1993 1194 1198
155. N. Mor, J. Vanderkolk, and L. Heifets Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages Antimicrob Agents Chemother 38 5 1994 1161 1164
156. B.A. Mueller, D.G. Brierton, S.R. Abel, and L. Bowman Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin Antimicrob Agents Chemother 38 9 1994 2101 2105
157. H. Nebenzahl-Guimaraes, K.R. Jacobson, M.R. Farhat, and M.B. Murray Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis J Antimicrob Chemother 69 2 2014 331 342
158. C.H. Nightingale, E.M. Grant, and R. Quintiliani Pharmacodynamics and pharmacokinetics of levofloxacin Chemotherapy 46 Suppl. 1 2000 6 14
159. H.M. Nijland, R. Ruslami, A.J. Suroto, D.M. Burger, B. Alisjahbana, R. van Crevel, and R.E. Aarnoutse Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis Clin Infect Dis Off Publ Infect Dis Soc Am 45 8 2007 1001 1007
160. Levofloxacin Tuberculosis 88 2 2008 119 121
161. Moxifloxacin Tuberculosis 88 2 2008 127 131
162. G.J. Noel, J.S. Bradley, R.E. Kauffman, C.M. Duffy, P.G. Gerbino, A. Arguedas, P. Bagchi, D.A. Balis, and J.L. Blumer Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders Pediatr Infect Dis J 26 10 2007 879 891
163. G.J. Noel, D.B. Goodman, S. Chien, B. Solanki, M. Padmanabhan, and J. Natarajan Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings J Clin Pharmacol 44 5 2004 464 473
164. G.J. Noel, J. Natarajan, S. Chien, T.L. Hunt, D.B. Goodman, and R. Abels Effects of three fluoroquinolones on QT interval in healthy adults after single doses Clin Pharmacol Ther 73 4 2003 292 303
165. E. Nuermberger, S. Tyagi, R. Tasneen, K.N. Williams, D. Almeida, I. Rosenthal, and J.H. Grosset Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis Antimicrob Agents Chemother 52 4 2008 1522 1524
166. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A.N. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am J Respir Crit Care Med 169 3 2004 421 426
167. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R.J. O'Brien, A.A. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis Am J Respir Crit Care Med 170 10 2004 1131 1134
168. E.W. Orenstein, S. Basu, N.S. Shah, J.R. Andrews, G.H. Friedland, A.P. Moll, N.R. Gandhi, and A.P. Galvani Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis Lancet Infect Dis 9 3 2009 153 161
169. L.A. Osborn, B. Skipper, I. Arellano, S.D. MacKerrow, and M.H. Crawford Results of resting and ambulatory electrocardiograms in patients with hypothyroidism and after return to euthyroid status Heart Dis 1 1 1999 8 11
170. M.P. Pai, S.E. Allen, and G.W. Amsden Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate J Cyst Fibros Off J Eur Cyst Fibros Soc 5 3 2006 153 157
171. J.H. Paton, and D.S. Reeves Clinical features and management of adverse effects of quinolone antibacterials Drug Saf 6 1 1991 8 27
172. J.C. Pechere Quinolones in intracellular infections Drugs 45 Suppl 3 1993 29 36
173. C.A. Peloquin, D.J. Hadad, L.P. Molino, M. Palaci, W.H. Boom, R. Dietze, and J.L. Johnson Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis Antimicrob Agents Chemother 52 3 2008 852 857
174. M. Pinon, C. Scolfaro, E. Bignamini, G. Cordola, I. Esposito, R. Milano, F. Mignone, C. Bertaina, and P.A. Tovo Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin Pediatrics 126 5 2010 e1253 e1256
175. S.C. Piscitelli, K. Spooner, B. Baird, A.T. Chow, C.L. Fowler, R.R. Williams, J. Natarajan, H. Masur, and R.E. Walker Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 43 9 1999 2323 2327
176. M.W. Pletz, A. De Roux, A. Roth, K.H. Neumann, H. Mauch, and H. Lode Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study Antimicrob Agents Chemother 48 3 2004 780 782
177. J. Poissy, A. Aubry, C. Fernandez, M.C. Lott, A. Chauffour, V. Jarlier, R. Farinotti, and N. Veziris Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? an answer from a murine model Antimicrob Agents Chemother 54 11 2010 4765 4771
178. R.E. Polk, D.P. Healy, J. Sahai, L. Drwal, and E. Racht Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers Antimicrob Agents Chemother 33 11 1989 1841 1844
179. E. Poluzzi, E. Raschi, D. Motola, U. Moretti, and F. De Ponti Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system Drug Saf Int J Med Toxicol Drug Exp 33 4 2010 303 314
180. A.D. Pranger, R. van Altena, R.E. Aarnoutse, D. van Soolingen, D.R. Uges, J.G. Kosterink, T.S. van der Werf, and J.W. Alffenaar Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Eur Respir J Off J Eur Soc Clin Respir Phys 38 4 2011 888 894
181. M.J. Pucci, M. Ackerman, J.A. Thanassi, C.M. Shoen, and M.H. Cynamon In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates Antimicrob Agents Chemother 54 8 2010 3478 3480
182. N. Rastogi, and M.C. Blom-Potar Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line Zentralblatt fur Bakteriologie Int J Med Microbiol 273 2 1990 195 199
183. N. Rastogi, and K.S. Goh In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin Antimicrob Agents Chemother 35 9 1991 1933 1936
184. N. Rastogi, K.S. Goh, A. Bryskier, and A. Devallois In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis Antimicrob Agents Chemother 40 7 1996 1610 1616
185. N. Rastogi, B.C. Ross, B. Dwyer, K.S. Goh, S. Clavel-Seres, V. Jeantils, and P. Cruaud Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 11 10 1992 901 907
186. E. Rey-Jurado, G. Tudo, J.P. de la Bellacasa, M. Espasa, and J. Gonzalez-Martin In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates Int J Antimicrob Agents 41 3 2013 278 280
187. E. Rey-Jurado, G. Tudo, D. Soy, and J. Gonzalez-Martin Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model Int J Antimicrob Agents 42 6 2013 524 530
188. P. Ribard, F. Audisio, M.F. Kahn, M. De Bandt, C. Jorgensen, G. Hayem, O. Meyer, and E. Palazzo Seven achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy J Rheumatol 19 9 1992 1479 1481
189. L. Richeldi, M. Covi, G. Ferrara, F. Franco, P. Vailati, E. Meschiari, L.M. Fabbri, and G. Velluti Clinical use of levofloxacin in the long-term treatment of drug resistant tuberculosis. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace/Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Universita di Napoli Secondo ateneo 57 1 2002 39 43
190. R. Ridzon, J.H. Kent, S. Valway, P. Weismuller, R. Maxwell, M. Elcock, J. Meador, S. Royce, A. Shefer, P. Smith, C. Woodley, and I. Onorato Outbreak of drug-resistant tuberculosis with second-generation transmission in a high school in California J Pediatr 131 6 1997 863 868
191. T. Rimmele, E. Boselli, D. Breilh, S. Djabarouti, J.C. Bel, R. Guyot, M.C. Saux, and B. Allaouchiche Diffusion of levofloxacin into bone and synovial tissues J Antimicrob Chemother 53 3 2004 533 535
192. J.C. Rodriguez, M. Ruiz, A. Climent, and G. Royo In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis Int J Antimicrob Agents 17 3 2001 229 231
193. J.C. Rodriguez, M. Ruiz, M. Lopez, and G. Royo In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis Int J Antimicrob Agents 20 6 2002 464 467
194. M.T. Rosanova, R. Lede, H. Capurro, V. Petrungaro, and P. Copertari Assessing fluoroquinolones as risk factor for musculoskeletal disorders in children: a systematic review and meta-analysis Arch Argent Pediatr 108 6 2010 524 531
195. I.M. Rosenthal, K. Williams, S. Tyagi, A.A. Vernon, C.A. Peloquin, W.R. Bishai, J.H. Grosset, and E.L. Nuermberger Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis Am J Respir Crit Care Med 172 11 2005 1457 1462
196. I.M. Rosenthal, M. Zhang, D. Almeida, J.H. Grosset, and E.L. Nuermberger Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 178 9 2008 989 993
197. M.J. Ruiz-Serrano, L. Alcala, L. Martinez, M. Diaz, M. Marin, M.J. Gonzalez-Abad, and E. Bouza In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs Antimicrob Agents Chemother 44 9 2000 2567 2568
198. R. Ruslami, A.R. Ganiem, S. Dian, L. Apriani, T.H. Achmad, A.J. van der Ven, G. Borm, R.E. Aarnoutse, and R. van Crevel Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial Lancet Infect Dis 13 1 2013 27 35
199. R. Rustomjee, C. Lienhardt, T. Kanyok, G.R. Davies, J. Levin, T. Mthiyane, C. Reddy, A.W. Sturm, F.A. Sirgel, J. Allen, D.J. Coleman, B. Fourie, and D.A. Mitchison A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 12 2 2008 128 138
200. H. Saito, K. Sato, H. Tomioka, and S. Dekio In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355) Tuber Lung Dis Off J Int Union Tuberc Lung Dis 76 5 1995 377 380
201. M.C. Sanguinetti, C. Jiang, M.E. Curran, and M.T. Keating A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel Cell 81 2 1995 299 307
202. K. Sato, H. Tomioka, C. Sano, T. Shimizu, K. Sano, K. Ogasawara, S. Cai, and T. Kamei Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines J Antimicrob Chemother 52 2 2003 199 203
203. U.B. Schaad Fluoroquinolone antibiotics in infants and children Infect Dis Clin N Am 19 3 2005 617 628
204. U.B. Schaad Use of quinolones in pediatrics Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 10 4 1991 355 360
205. U.B. Schaad Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 26 10 2007 865 867
206. H.S. Schaaf, R.P. Gie, M. Kennedy, N. Beyers, P.B. Hesseling, and P.R. Donald Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up Pediatrics 109 5 2002 765 771
207. H.S. Schaaf, B.J. Marais, A. Whitelaw, A.C. Hesseling, B. Eley, G.D. Hussey, and P.R. Donald Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases BMC Infect Dis 7 2007 140
208. J.J. Schentag, A.K. Meagher, and A. Forrest Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials Ann Pharmacother 37 10 2003 1478 1488
209. J.A. Seddon, A.C. Hesseling, H. Finlayson, K. Fielding, H. Cox, J. Hughes, P. Godfrey-Faussett, and H.S. Schaaf Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study Clin Infect Dis Off Publ Infect Dis Soc Am 57 12 2013 1676 1684
210. J.A. Seddon, A.C. Hesseling, L. Finlayson, and H. Schaaf Toxicity and tolerabilitiy of multidrug-resistant tuberculosis preventive treatment in children 43rd world conference on lung health of the International Union against tuberculosis and lung disease (The Union) 2012 The International Journal of Tuberculosis and Lung Disease Kuala Lumpur, Malaysia
211. J.A. Seddon, A.C. Hesseling, P. Godfrey-Faussett, and H.S. Schaaf High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study Thorax 69 5 2014 458 464
212. J.A. Seddon, C.M. Perez-Velez, H.S. Schaaf, J.J. Furin, B.J. Marais, M. Tebruegge, A. Detjen, A.C. Hesseling, S. Shah, L.V. Adams, J.R. Starke, S. Swaminathan, and M.C. Becerra Consensus statement on research definitions for drug-resistant tuberculosis in children J Pediatr Infect Dis Soc 2 2 2013 100 109
213. J.A. Seddon, and D. Shingadia Epidemiology and disease burden of tuberculosis in children: a global perspective Infect Drug Resist 7 2014 153 165
214. R.K. Shandil, R. Jayaram, P. Kaur, S. Gaonkar, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy Antimicrob Agents Chemother 51 2 2007 576 582
215. C.M. Shoen, M.S. DeStefano, M.R. Sklaney, B.J. Monica, A.M. Slee, and M.H. Cynamon Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis J Antimicrob Chemother 53 4 2004 641 645
216. M. Singh, D.S. Chauhan, P. Gupta, R. Das, R.K. Srivastava, P. Upadhyay, P. Singh, K. Srivastava, J. Faujdar, G.P. Jaudaun, V.S. Yadav, V.D. Sharma, K. Venkatesan, S. Sachan, P. Sachan, K. Katoch, and V.M. Katoch In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India Indian J Med Res 129 5 2009 542 547
217. M. Singh, G.P. Jadaun, Ramdas, K. Srivastava, V. Chauhan, R. Mishra, K. Gupta, S. Nair, D.S. Chauhan, V.D. Sharma, K. Venkatesan, and V.M. Katoch Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates Indian J Med Res 133 2011 535 540
218. F.A. Sirgel, P.R. Donald, J. Odhiambo, W. Githui, K.C. Umapathy, C.N. Paramasivan, C.M. Tam, K.M. Kam, C.W. Lam, K.M. Sole, and D.A. Mitchison A multicentre study of the early bactericidal activity of anti-tuberculosis drugs J Antimicrob Chemother 45 6 2000 859 870
219. F.A. Sirgel, R.M. Warren, E.M. Streicher, T.C. Victor, P.D. van Helden, and E.C. Bottger gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis J Antimicrob Chemother 67 5 2012 1088 1093
220. P.S. Skinner, S.K. Furney, D.A. Kleinert, and I.M. Orme Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis Antimicrob Agents Chemother 39 3 1995 750 753
221. R. Stahlmann Children as a special population at risk-quinolones as an example for xenobiotics exhibiting skeletal toxicity Arch Toxicol 77 1 2003 7 11
222. R. Stahlmann Clinical toxicological aspects of fluoroquinolones Toxicol Lett 127 1-3 2002 269 277
223. R. Stahlmann, and H. Lode Safety overview: toxicity, adverse events and drug interactions V.T. Andriole, The quinolones 2000 Academic Press San Diego 397 453
224. R. Stahlmann, and H. Lode Safety overview. Toxicity, adverse effects, and drug interactions V. Andriole, The quinolones 1998 Academic Press San Diego, California 369 415
225. R. Stahlmann, and H. Lode Toxicity of quinolones Drugs 58 Suppl. 2 1999 37 42
226. H. Stass, A. Dalhoff, D. Kubitza, and U. Schuhly Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects Antimicrob Agents Chemother 42 8 1998 2060 2065
227. H. Stass, and D. Kubitza Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers Clin Pharmacokinet 40 Suppl. 1 2001 33 38
228. H. Stass, and D. Kubitza Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man J Antimicrob Chemother 43 Suppl. B 1999 83 90
229. H. Stass, and D. Kubitza Profile of moxifloxacin drug interactions Clin Infect Dis Off Publ Infect Dis Soc Am 32 Suppl. 1 2001 S47 S50
230. H. Stass, D. Kubitza, and U. Schuhly Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration Clin Pharmacokinet 40 Suppl. 1 2001 1 9
231. E.A. Sullivan, B.N. Kreiswirth, L. Palumbo, V. Kapur, J.M. Musser, A. Ebrahimzadeh, and T.R. Frieden Emergence of fluoroquinolone-resistant tuberculosis in New York City Lancet 345 8958 1995 1148 1150
232. S. Sulochana, D.A. Mitchison, G. Kubendiren, P. Venkatesan, and C.N. Paramasivan Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis J Chemother 21 2 2009 127 134
233. S. Swaminathan, and S.K. Kabra Childhood tuberculosis challenges and way forward Indian J Pediatr 78 3 2011 319 320
234. H.E. Takiff, L. Salazar, C. Guerrero, W. Philipp, W.M. Huang, B. Kreiswirth, S.T. Cole, W.R. Jacobs Jr., and A. Telenti Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations Antimicrob Agents Chemother 38 4 1994 773 780
235. C.K. Tan, C.C. Lai, C.H. Liao, C.H. Chou, H.L. Hsu, Y.T. Huang, and P.R. Hsueh Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis J Antimicrob Chemother 64 2 2009 428 429
236. H. Tatsumi, H. Senda, S. Yatera, Y. Takemoto, M. Yamayoshi, and K. Ohnishi Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals J Toxicol Sci 3 4 1978 357 367
237. E.E. Telzak, K.D. Chirgwin, E.T. Nelson, J.P. Matts, K.A. Sepkowitz, C.A. Benson, D.C. Perlman, and W.M. El-Sadr Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 3 4 1999 337 343
238. J. Texier-Maugein, M. Mormede, J. Fourche, and C. Bebear In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria Eur J Clin Microbiol 6 5 1987 584 586
239. S. Thee, A.J. Garcia-Prats, H.R. Draper, H.M. McIlleron, L. Wiesner, S. Castel, H.S. Schaaf, and A.C. Hesseling The pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis Clin Infect Dis 2014
240. S. Thee, A.J. Garcia-Prats, H.M. McIlleron, L. Wiesner, S. Castel, J. Norman, H.R. Draper, P.L. van der Merwe, A.C. Hesseling, and H.S. Schaaf Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children Antimicrob Agents Chemother 58 5 2014 2948 2951
241. G.E. Thwaites, S.M. Bhavnani, T.T. Chau, J.P. Hammel, M.E. Torok, S.A. Van Wart, P.P. Mai, D.K. Reynolds, M. Caws, N.T. Dung, T.T. Hien, R. Kulawy, J. Farrar, and P.G. Ambrose Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis Antimicrob Agents Chemother 55 7 2011 3244 3253
242. H. Tomioka, H. Saito, and K. Sato Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin Antimicrob Agents Chemother 37 6 1993 1259 1263
243. H. Tomioka, K. Sato, T. Akaki, H. Kajitani, S. Kawahara, and M. Sakatani Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex Antimicrob Agents Chemother 43 12 1999 3001 3004
244. H. Tomioka, K. Sato, H. Kajitani, T. Akaki, and S. Shishido Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex Antimicrob Agents Chemother 44 2 2000 283 286
245. C. Truffot-Pernot, B. Ji, and J. Grosset Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments Tubercle 72 1 1991 57 64
246. M. Tsukamura In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280) Am Rev Respir Dis 131 3 1985 348 351
247. M. Tsukamura, E. Nakamura, S. Yoshii, and H. Amano Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis Am Rev Respir Dis 131 3 1985 352 356
248. Tuberculosis Research Centre, C Shortening short course chemotherapy: a randomized clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using of-loxacin in the intensive phase Indian J Tuberc 49 2002 27 38
249. C. Upton Sleep disturbance in children treated with ofloxacin BMJ 309 6966 1994 1411
250. S. Vacher, J.L. Pellegrin, F. Leblanc, J. Fourche, and J. Maugein Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin J Antimicrob Chemother 44 5 1999 647 652
251. R. Valaitis, R. Martin-Misener, S.T. Wong, M. MacDonald, D. Meagher-Stewart, P. Austin, J. Kaczorowski, O.M. L, and R. Savage Methods, strategies and technologies used to conduct a scoping literature review of collaboration between primary care and public health Prim Health Care Res Dev 13 3 2012 219 236
252. G. Valerio, P. Bracciale, V. Manisco, M. Quitadamo, G. Legari, and S. Bellanova Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results J Chemother 15 1 2003 66 70
253. F. Van Bambeke, and P.M. Tulkens Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes Drug Saf Int J Med Toxicol Drug Exp 32 5 2009 359 378
254. D. Van Caekenberghe Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp J Antimicrob Chemother 26 3 1990 381 386
255. B.V. Velayutham, I.S. Allaudeen, G.N. Sivaramakrishnan, V. Perumal, D. Nair, P. Chinnaiyan, P.K. Paramasivam, B. Dhanaraj, R.K. Santhanakrishnan, G.P. Navaneethapandian, M.K. Marimuthu, V. Kumar, C. Kandasamy, K. Dharuman, T. Elangovan, M. Narasimhan, S. Rathinam, G. Vadivelu, P. Rathinam, C. Chockalingam, L. Jayabal, S. Swaminathan, and J.M. Shaheed Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India Clin Infect Dis 59 10 2014 e142 e149
256. M. Verho, V. Malerczyk, E. Dagrosa, and A. Korn The effect of food on the pharmacokinetics of ofloxacin Curr Med Res Opin 10 3 1986 166 171
257. N. Veziris, C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo Antimicrob Agents Chemother 47 10 2003 3117 3122
258. A. Von Groll, A. Martin, P. Jureen, S. Hoffner, P. Vandamme, F. Portaels, J.C. Palomino, and P.A. da Silva Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB Antimicrob Agents Chemother 53 10 2009 4498 4500
259. J.Y. Wang, P.R. Hsueh, I.S. Jan, L.N. Lee, Y.S. Liaw, P.C. Yang, and K.T. Luh Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas Thorax 61 10 2006 903 908
260. J.Y. Wang, J.T. Wang, T.H. Tsai, C.L. Hsu, C.J. Yu, P.R. Hsueh, L.N. Lee, and P.C. Yang Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 14 1 2010 65 71
261. K.M. Watt, M.M. Massaro, B. Smith, M. Cohen-Wolkowiez, D.K. Benjamin Jr., and M.M. Laughon Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis Pediatr Infect Dis J 31 2 2012 197 199
262. M. Weiner, W. Burman, C.C. Luo, C.A. Peloquin, M. Engle, S. Goldberg, V. Agarwal, and A. Vernon Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin Antimicrob Agents Chemother 51 8 2007 2861 2866
263. A.P. Winrow, and G. Supramaniam Benign intracranial hypertension after ciprofloxacin administration Arch Dis Child 65 10 1990 1165 1166
264. R. Wise, and D. Honeybourne Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract Eur Respir J 14 1 1999 221 229
265. J.M. Woodcock, J.M. Andrews, F.J. Boswell, N.P. Brenwald, and R. Wise In vitro activity of BAY 12-8039, a new fluoroquinolone Antimicrob Agents Chemother 41 1 1997 101 106
266. World Health Organization global tuberculosis report 2014 2014 WHO Geneva, Switzerland WHO/HTM/TB/2014.08. 2014
267. World Health Organization, WHO WHO/HTM/TB/2010.3 Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response 2010 46 47
268. D.H. Wright, G.H. Brown, M.L. Peterson, and J.C. Rotschafer Application of fluoroquinolone pharmacodynamics J Antimicrob Chemother 46 5 2000 669 683
269. C. Xu, B.N. Kreiswirth, S. Sreevatsan, J.M. Musser, and K. Drlica Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis J Infect Dis 174 5 1996 1127 1130
270. C.L. Yee, C. Duffy, P.G. Gerbino, S. Stryker, and G.J. Noel Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin Pediatr Infect Dis J 21 6 2002 525 529
271. W.W. Yew, C.K. Chan, C.H. Chau, C.M. Tam, C.C. Leung, P.C. Wong, and J. Lee Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens Chest 117 3 2000 744 751
272. W.W. Yew, C.K. Chan, C.C. Leung, C.H. Chau, C.M. Tam, P.C. Wong, and J. Lee Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong Chest 124 4 2003 1476 1481
273. W.W. Yew, S.Y. Kwan, W.K. Ma, M.A. Khin, and P.Y. Chau In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis J Antimicrob Chemother 26 2 1990 227 236
274. Y.S. Yoon, H.J. Lee, H.I. Yoon, C.G. Yoo, Y.W. Kim, S.K. Han, Y.S. Shim, and J.J. Yim Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 9 11 2005 1215 1219
275. T. Yoshimatsu, E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis Antimicrob Agents Chemother 46 6 2002 1875 1879
276. J.H. Yuk, C.H. Nightingale, R. Quintiliani, and K.R. Sweeney Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers Antimicrob Agents Chemother 35 2 1991 384 386
277. Q. Zhang, Y. Liu, S. Tang, W. Sha, and H. Xiao Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China Cell Biochem Biophys 67 3 2013 957 963
278. X. Zhao, and K. Drlica Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies Clin Infect Dis Off Publ Infect Dis Soc Am 33 Suppl. 3 2001 S147 S156
279. J. Zhou, Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J.M. Musser, and K. Drlica Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations J Infect Dis 182 2 2000 517 525
280. M. Zhu, J.J. Stambaugh, S.E. Berning, A.E. Bulpitt, E.S. Hollender, M. Narita, D. Ashkin, and C.A. Peloquin Ofloxacin population pharmacokinetics in patients with tuberculosis Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 6 6 2002 503 509
281. S.P. Zvada, P. Denti, H. Geldenhuys, S. Meredith, D. van As, M. Hatherill, W. Hanekom, L. Wiesner, U.S. Simonsson, A. Jindani, T. Harrison, and H.M. McIlleron Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine Antimicrob Agents Chemother 56 8 2012 4471 4473
282. S.P. Zvada, P. Denti, F.A. Sirgel, E. Chigutsa, M. Hatherill, S. Charalambous, S. Mungofa, L. Wiesner, U.S. Simonsson, A. Jindani, T. Harrison, and H.M. McIlleron Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients Antimicrob Agents Chemother 58 1 2014 503 510